Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The promoter specificity of transcriptional activators is generally thought to be conferred by the specificity of the DNA-binding domain, which brings the activation domain to the appropriate promoter sequence. We show here, however, that Oct-1 and
Oct-2
can differentially activate transcription not through DNA binding specificity but instead through the use of promoter-selective activation domains. These distinct activation domains lead to stimulation of the U2 small nuclear RNA promoter by Oct-1 and an mRNA promoter by
Oct-2
. An
Oct-2
variant, called Oct-2B, differs from
Oct-2
by an Oct-1-related C-terminal extension that results from alternative splicing. This variant gains the ability to activate the U2 small nuclear RNA promoter. Thus, the promoter selectivity of a
transcriptional activator
can be changed, in this case by alternative splicing, without affecting its DNA binding specificity.
...
PMID:Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter. 173 80
Oct-2
, a POU homeodomain protein expressed primarily in B cells, is a powerful
transcriptional activator
that binds to DNA at sites appropriately placed for major effects on immunoglobulin gene expression. Our examination of B cell development and function in
Oct-2
null mice did not support an essential role for
Oct-2
early in B cell development. Rather,
Oct-2
was required later, when B cells were induced to differentiate to antibody-secreting cells. We show here that
Oct-2
is not required for normal immunoglobulin production by mature B lymphocytes. Instead, it is essential for a normal proliferative response to polyclonal mitogens. Responses to signals from activated T cells are unaffected. The requirement for
Oct-2
maps to an early activation step in G1, during which B cells make the commitment to progress through the cell cycle and to divide.
...
PMID:Oct-2 is required early in T cell-independent B cell activation for G1 progression and for proliferation. 760 Feb 91
Interleukin-5 (IL-5) controls the development of eosinophilia and contributes to a number of disease states including asthma. Expression of IL-5 is inducible under tight transcriptional regulation. This requires the contribution of several promoter elements; however, the conserved lymphokine element 0 (CLE0) in particular, is essential for expression of IL-5. In this study, we report the nuclear factors which regulate human IL-5 CLE0 activity in the human cell line PER-117. Using specific antibodies, we identified the transcriptional factors Oct-1 and
Oct-2
binding to the 5' region of the CLE0 element. The involvement of Oct factors with CLE0 has not been reported previously in any of the lymphokines. In addition, the CLE0 element also appeared to complex with the
transcriptional activator
AP-1, consisting of the family members Jun D and Fra-2. We observed the binding of Oct-1 to be constitutive in comparison to
Oct-2
and AP-1, both of which were induced in response to cell activation by PMA/A23187. Although the interaction of all three factors with CLE0 was closely linked and overlapping, residues critical to their binding were identified. We demonstrate, using site-directed mutagenesis and cotransfection experiments, that the CLE0 element is indispensable for IL-5 promoter activity and that Octamer factors contribute to the positive regulation of the hIL-5 gene.
...
PMID:The activity of the human interleukin-5 conserved lymphokine element 0 is regulated by octamer factors in human cells. 1049 Nov 86